Inhibition of α-Amylase and α-Glucosidase by New β-Aminopropionamidoxime Derivatives

• DOI: 10.1007/s11094-019-01966-5
• Publication Date: 2019-06-07T04:42:21Z
• Authors: L. A. Kayukova; A. B. Uzakova; G. P. Baitursynova; G. T. Dyusembaeva; Z. T. Shul’gau; A. E. Gulyaev; Sh. D. Sergazy
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

New antidiabetic agents are being sought because of the global problem with diabetes. Amidoxime derivatives are known to have antidiabetic activity. β-Aminopropionamidoxime bases and pharmacologically acceptable salts of O-aroyl-β-(morpholin-1-yl)propionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles were screened in vitro for antidiabetic activity manifested as inhibition of α-amylase and α-glucosidase. Compounds with pronounced antidiabetic properties were identified. The series of 3,5-disubstituted 1,2,4-oxadiazoles were more active than the series of O-aroyl-β-aminopropionamidoximes. The results could be used for further in vivo screening of the antidiabetic properties of the most promising compounds with a preliminary assessment of their mean toxic doses in animals.